AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studySystematic reviewPeer-reviewed
Human Studies on Anti-CD20 Monoclonal Antibodies in Multiple Sclerosis
A systematic review analyzed the use of anti-CD20 monoclonal antibodies in treating multiple sclerosis (MS) and other autoimmune CNS disorders. It found that these therapies effectively suppress inflammatory activity. Strategies like Extended Interval Dosing (EID) and dose-reduction may help manage long-term treatment risks.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
This review highlights important treatment optimization strategies that could enhance the safety and efficacy of anti-CD20 therapies in MS.
What this does not prove
The conclusions are based on heterogeneous data from retrospective studies and do not provide formal recommendations for practice.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-09
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceOptimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review. ↗DOI: 10.1007/s40120-026-01048-1
Supporting passages (8)
study designThis review, a joint effort of the Steering Committees of the Italian Neuroimmunology Association and of the Neuroimmunology Study Group of the Italian Society of Neurology, summarizes current evidence on long-term anti-CD20 treatment optimization across autoimmune central nervous system (CNS) disorders, with particular focus on cumulative exposure, extended-interval dosing, dose reduction, B-cell-guided retreatment, treatment discontinuation, and safety monitoring.
subjectsThese agents robustly suppress inflammatory disease activity through prolonged B-cell depletion; however, cumulative exposure is associated with increased infection risk, hypogammaglobulinemia, and impaired vaccine-induced humoral responses.
peer reviewedThis review, a joint effort of the Steering Committees of the Italian Neuroimmunology Association and of the Neuroimmunology Study Group of the Italian Society of Neurology, summarizes current evidence on long-term anti-CD20 treatment optimization across autoimmune central nervous system (CNS) disorders, with particular focus on cumulative exposure, extended-interval dosing, dose reduction, B-cell-guided retreatment, treatment discontinuation, and safety monitoring.
findingsAnti-CD20 monoclonal antibodies have become central therapies for multiple sclerosis (MS) and other autoimmune disorders of the central nervous system, including neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and autoimmune encephalitis.
findingsIn recent years, extended interval dosing (EID) and dose-reduction strategies have emerged as potential approaches to mitigate long-term safety concerns while preserving therapeutic efficacy.
limitationsHowever, the available evidence remains heterogeneous and largely based on retrospective real-world cohorts.
limitationsThis review does not provide formal consensus recommendations but highlights disease-specific considerations that may help clinicians balance sustained disease control against cumulative treatment-related risks.
publication datePublication date: 2026-10-09
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.